Abstract:Identifying and refining clinically significant patient stratification is a critical step toward realizing the promise of precision medicine in asthma. Several peripheral blood hallmarks, including total peripheral blood eosinophil count (BEC) and immunoglobulin E (IgE) levels, are routinely used in asthma clinical practice for endotype classification and predicting response to state-of-the-art targeted biologic drugs. However, these biomarkers appear ineffective in predicting treatment outcomes in some patients, and they differ in distribution between racially and ethnically diverse populations, potentially compromising medical care and hindering health equity due to biases in drug eligibility. Here, we propose constructing an unbiased patient stratification score based on DNA methylation (DNAm) and utilizing it to refine the efficacy of hallmark biomarkers for predicting drug response. We developed Phenotype Aware Component Analysis (PACA), a novel contrastive machine-learning method for learning combinations of DNAm sites reflecting biomedically meaningful patient stratifications. Leveraging whole-blood DNAm from Latino (discovery; n=1,016) and African American (replication; n=756) pediatric asthma case-control cohorts, we applied PACA to refine the prediction of bronchodilator response (BDR) to the short-acting β2-agonist albuterol, the most used drug to treat acute bronchospasm worldwide. While BEC and IgE correlate with BDR in the general patient population, our PACA-derived DNAm score renders these biomarkers predictive of drug response only in patients with high DNAm scores. BEC correlates with BDR in patients with upper-quartile DNAm scores (OR 1.12; 95% CI [1.04, 1.22]; P=7.9 e-4) but not in patients with lower-quartile scores (OR 1.05; 95% CI [0.95, 1.17]; P=0.21); and IgE correlates with BDR in above-median (OR for response 1.42; 95% CI [1.24, 1.63]; P=3.9e-7) but not in below-median patients (OR 1.05; 95% CI [0.92, 1.2]; P=0.57). These results hold within the commonly recognized type 2 (T2)-high asthma endotype but not in T2-low patients, suggesting that our DNAm score primarily represents an unknown variation of T2 asthma. Among T2-high patients with high DNAm scores, elevated BEC or IgE also corresponds to baseline clinical presentation that is known to benefit more from biologic treatment, including higher exacerbation scores, higher allergen sensitization, lower BMI, more recent oral corticosteroids prescription, and lower lung function. Our findings suggest that BEC and IgE, the traditional asthma biomarkers of T2-high asthma, are poor biomarkers for millions worldwide. Revisiting existing drug eligibility criteria relying on these biomarkers in asthma medical care may enhance precision and equity in treatment.

Late Breaking Abstract - Patient stratification of two asthma populations reveal distinct genetic and mechanistic differences between T2-high and T2-low asthma

Lung function, airway and peripheral basophils and eosinophils are associated with molecular pharmacogenomic endotypes of steroid response in severe asthma

A Strategy for High-Dimensional Multivariable Analysis Classifies Childhood Asthma Phenotypes from Genetic, Immunological, and Environmental Factors

Pharmacodynamic genome-wide association study identifies new responsive loci for glucocorticoid intervention in asthma

Epigenetic patient stratification via contrastive machine learning refines hallmark biomarkers in minoritized children with asthma

Epigenetic Approaches to Identifying Asthma Endotypes

Integrative genetic and metabolite profiling analysis suggests altered phosphatidylcholine metabolism in asthma.

De novo identification of complex traits associated with asthma

Potential drug targets for asthma identified in the plasma and brain through Mendelian randomization analysis

Investigational approaches for unmet need in severe asthma

Endotypes of severe neutrophilic and eosinophilic asthma from multi-omics integration of U-BIOPRED sputum samples

Type 2‐low asthma phenotypes by integration of sputum transcriptomics and serum proteomics

Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease

T-high asthma phenotypes across life span

From gene identifications to therapeutic targets for asthma: Focus on great potentials of TSLP, ORMDL3, and GSDMB

Genomic Predictors of Asthma Phenotypes and Treatment Response

Gene signatures in U-BIOPRED severe asthma for molecular phenotyping and precision medicine: time for clinical use

Pathway Discovery Using Transcriptomic Profiles in Adult-Onset Severe Asthma.

Unspecified asthma, childhood-onset, and adult-onset asthma have different causal genes: a Mendelian randomization analysis

Epigenomic partitioning of a polygenic risk score for asthma reveals distinct genetically driven disease pathways

Prioritization of candidate causal genes in GWAS signals of asthma in UK Biobank